Compare · ILMN vs OSA
ILMN vs OSA
Side-by-side comparison of Illumina Inc. (ILMN) and ProSomnus Inc. (OSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and OSA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $51.89B.
- ILMN has hit the wire 5 times in the past 4 weeks while OSA has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for OSA).
- Company
- Illumina Inc.
- ProSomnus Inc.
- Price
- $127.93+2.01%
- $0.50-15.25%
- Market cap
- $51.89B
- -
- 1M return
- +1.37%
- -
- 1Y return
- +65.69%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ILMN
- DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows
- Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
- Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
- SEC Form DEFA14A filed by Illumina Inc.
- SEC Form DEF 14A filed by Illumina Inc.
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Meister Keith A.
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Illumina Announces Changes to Board of Directors
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
Latest OSA
- ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 10-K/A filed by ProSomnus Inc. (Amendment)
- SEC Form 25-NSE filed by ProSomnus Inc.
- ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- ProSomnus Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-K filed by ProSomnus Inc.
- ProSomnus Q4 Sales $7.84M Beat $7.37M Estimate
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- ProSomnus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits